Reviva Pharmaceuticals (NASDAQ:RVPH) Announces Quarterly Earnings Results

Reviva Pharmaceuticals (NASDAQ:RVPH) issued its quarterly earnings data on Saturday. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.37, FiscalAI reports.

Reviva Pharmaceuticals Price Performance

Shares of RVPH stock opened at $0.74 on Monday. The firm has a market cap of $4.78 million, a P/E ratio of -0.08 and a beta of 0.10. Reviva Pharmaceuticals has a 1-year low of $0.67 and a 1-year high of $23.20. The firm has a fifty day moving average of $4.27 and a two-hundred day moving average of $7.91.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth approximately $58,000. XTX Topco Ltd increased its holdings in shares of Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after acquiring an additional 63,893 shares during the last quarter. Lido Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Finally, Millennium Management LLC raised its position in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on RVPH. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Chardan Capital reiterated a “buy” rating and issued a $40.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, March 14th. D. Boral Capital lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $66.67.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.